Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study.
The efficacy and safety of long-acting propranolol (LA.P), 160 mg once-daily, in the prophylactic treatment of migraine have been tested against placebo in a multicentric, double-blind, randomized study. The two groups are compared in a parallel manner over a treatment period of 12 weeks, following a 4-week placebo run-in period. Fifty-five of the 74 patients who entered the trial were included at the end of the run-in period. Forty-one patients completed the study. None of the 14 patients who withdrew from the study did so because of side effects. The statistical analysis was done according to the "intention to treat" principle. LA.P was significantly more effective than placebo in reducing the frequency of migraine attacks (p = 0.01 by variance analysis). LA.P reduced the average number of monthly crises by 48% on day 84. There was a slight but significant reduction of the systolic blood pressure and heart rate in the erect position, but there was no significant difference between LA.P and placebo regarding either the number of complaints or the number of side effects elicited out of a 17-item questionnaire. None of the observed side effects led to a withdrawal from treatment.
Pradalier
A
A
Hôpital Rothschild, Paris, France.
Serratrice
G
G
Collard
M
M
Hirsch
E
E
Feve
J
J
Masson
M
M
Masson
C
C
Dry
J
J
Koulikovsky
G
G
Nguyen
G
G
D000328:Adult; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000517:prevention & control*; D011433:Propranolol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D003692:Delayed-Action Preparations; D011433:Propranolol